TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Novartis Sverige AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
1,434,854
|
1,327,294
|
1,165,183 |
| Financial expenses |
11,662
|
8,134
|
6,106 |
| Earnings before taxes |
54,462
|
38,138
|
41,279 |
| EBITDA |
67,752
|
47,430
|
49,173 |
| Total assets |
675,837
|
498,680
|
467,207 |
| Current assets |
667,381
|
489,368
|
457,221 |
| Current liabilities |
244,448
|
229,143
|
216,600 |
| Equity capital |
97,982
|
88,578
|
66,891 |
| - share capital |
3,247
|
3,358
|
3,341 |
| Employees (average) |
142
|
189
|
206 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
14.5%
|
17.8%
|
14.3% |
| Turnover per employee |
10,105
|
7,023
|
5,656 |
| Profit as a percentage of turnover |
3.8%
|
2.9%
|
3.5% |
| Return on assets (ROA) |
9.8%
|
9.3%
|
10.1% |
| Current ratio |
273.0%
|
213.6%
|
211.1% |
| Return on equity (ROE) |
55.6%
|
43.1%
|
61.7% |
| Change turnover |
151,461
|
156,111
|
64,708 |
| Change turnover % |
12%
|
13%
|
6% |
| Chg. No. of employees |
-47
|
-17
|
-10 |
| Chg. No. of employees % |
-25%
|
-8%
|
-5% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.